{"transactions":[{"id":989864,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-24T21:05:28.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."},{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant."}],"balance_after":13500,"derivative":{"exercise_price":1,"expiration_date":"2035-11-19","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001104659-25-115407","document":"tm2532045-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465925115407/tm2532045-1_4seq1.xml","form_type":"4"}},{"id":1094990,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:21:50.000Z","date":"2025-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (\"Merger Sub I\"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (\"Merger Sub II,\") and together with Merger Sub I, the \"Merger Subs\"), Kineta, Inc., a Delaware corporation (\"Kineta\") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the \"First Merger\"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the \"Surviving Corporation\"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the \"Second Merger\" and together with the First Merger, the \"Mergers\"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.28,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-092994","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025092994/ownership.xml","form_type":"4"}},{"id":1094989,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:21:50.000Z","date":"2025-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (\"Merger Sub I\"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (\"Merger Sub II,\") and together with Merger Sub I, the \"Merger Subs\"), Kineta, Inc., a Delaware corporation (\"Kineta\") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the \"First Merger\"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the \"Surviving Corporation\"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the \"Second Merger\" and together with the First Merger, the \"Mergers\"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.28,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-25-092994","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025092994/ownership.xml","form_type":"4"}},{"id":1094988,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T16:21:50.000Z","date":"2025-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16571,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (\"Merger Sub I\"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (\"Merger Sub II,\") and together with Merger Sub I, the \"Merger Subs\"), Kineta, Inc., a Delaware corporation (\"Kineta\") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the \"First Merger\"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the \"Surviving Corporation\"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the \"Second Merger\" and together with the First Merger, the \"Mergers\"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the First Merger (the \"Effective Time\"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share (\"Kineta Common Stock\"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share (\"TuHURA Common Stock\"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-092994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025092994/ownership.xml","form_type":"4"}},{"id":1101659,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:49:03.000Z","date":"2025-06-23","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the \"Company\") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation (\"TuHURA\"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025."}],"balance_after":0,"derivative":{"exercise_price":0.611,"expiration_date":"2034-09-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-25-090137","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090137/ownership.xml","form_type":"4"}},{"id":1101658,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:49:03.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18141,"source":{"system":"sec-edgar","filing":"0000950170-25-090137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090137/ownership.xml","form_type":"4"}},{"id":1101657,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:49:03.000Z","date":"2025-06-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":4706,"price":0.26,"value":1223.56,"ownership":{"direct":true},"balance_after":12141,"source":{"system":"sec-edgar","filing":"0000950170-25-090137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090137/ownership.xml","form_type":"4"}},{"id":1101656,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-25T21:49:03.000Z","date":"2025-06-23","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":0.611,"value":7637.5,"ownership":{"direct":true},"balance_after":16847,"source":{"system":"sec-edgar","filing":"0000950170-25-090137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017025090137/ownership.xml","form_type":"4"}},{"id":1304247,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-13T21:32:54.000Z","date":"2025-01-10","kind":"purchase","planned":false,"acquired":true,"shares":18382,"price":2.72,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025."}],"balance_after":18382,"source":{"system":"sec-edgar","filing":"0001104659-25-003061","document":"tm253156-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465925003061/tm253156-4_4seq1.xml","form_type":"4"}},{"id":1352558,"issuer":{"id":6906,"kind":"organization","name":"iBio, Inc.","symbol":"IBIO"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-11-25T21:31:45.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":12600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over three years commencing on the date of the grant."},{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over three years commencing on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over three years commencing on the date of the grant."}],"balance_after":12600,"derivative":{"exercise_price":2.45,"expiration_date":"2034-11-20","underlying":"Common Stock","underlying_shares":12600},"source":{"system":"sec-edgar","filing":"0001104659-24-122589","document":"tm2429436-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465924122589/tm2429436-2_4seq1.xml","form_type":"4"}},{"id":1413792,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-05T16:18:34.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in equal quarterly installments over one year following June 21, 2024, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.611,"expiration_date":"2034-09-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-24-104011","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000095017024104011/ownership.xml","form_type":"4"}},{"id":1638006,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-16T21:13:51.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":false,"shares":10625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":31875,"derivative":{"underlying":"Common Stock","underlying_shares":10625},"source":{"system":"sec-edgar","filing":"0000950170-24-016687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000095017024016687/ownership.xml","form_type":"4"}},{"id":1638005,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-16T21:13:51.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":35625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":35625,"derivative":{"underlying":"Common Stock","underlying_shares":35625},"source":{"system":"sec-edgar","filing":"0000950170-24-016687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000095017024016687/ownership.xml","form_type":"4"}},{"id":1638004,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:13:51.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":287905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively."}],"balance_after":287905,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":287905},"source":{"system":"sec-edgar","filing":"0000950170-24-016687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000095017024016687/ownership.xml","form_type":"4"}},{"id":1638003,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:13:51.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":213750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":213750,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":213750},"source":{"system":"sec-edgar","filing":"0000950170-24-016687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000095017024016687/ownership.xml","form_type":"4"}},{"id":1638002,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-16T21:13:51.000Z","date":"2024-02-16","kind":"sale","planned":true,"acquired":false,"shares":3939,"price":1.08,"value":4254.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":182442,"source":{"system":"sec-edgar","filing":"0000950170-24-016687","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000095017024016687/ownership.xml","form_type":"4"}},{"id":1638001,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-16T21:13:51.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":true,"shares":10625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":186381,"source":{"system":"sec-edgar","filing":"0000950170-24-016687","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000095017024016687/ownership.xml","form_type":"4"}},{"id":1753099,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-31T21:39:11.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":false,"shares":13209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":13209,"derivative":{"underlying":"Common Stock","underlying_shares":13209},"source":{"system":"sec-edgar","filing":"0000899243-23-020077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323020077/doc4.xml","form_type":"4"}},{"id":1753098,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-31T21:39:11.000Z","date":"2023-04-27","kind":"grant","planned":true,"acquired":true,"shares":26418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":26418,"derivative":{"underlying":"Common Stock","underlying_shares":26418},"source":{"system":"sec-edgar","filing":"0000899243-23-020077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323020077/doc4.xml","form_type":"4"}},{"id":1753097,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-31T21:39:11.000Z","date":"2023-10-30","kind":"sale","planned":true,"acquired":false,"shares":4066,"price":1.35,"value":5489.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 21, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.35 to $1.365, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":175756,"source":{"system":"sec-edgar","filing":"0000899243-23-020077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323020077/doc4.xml","form_type":"4"}},{"id":1753096,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-31T21:39:11.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":true,"shares":13209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."}],"balance_after":179822,"source":{"system":"sec-edgar","filing":"0000899243-23-020077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323020077/doc4.xml","form_type":"4"}},{"id":1910074,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-05-01T16:43:22.000Z","date":"2023-04-27","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 42,500 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,121 shares of common stock acquired under the Issuer's employee stock purchase plan."}],"balance_after":166613,"source":{"system":"sec-edgar","filing":"0000899243-23-011944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323011944/doc4.xml","form_type":"4"}},{"id":1919518,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-14T16:06:14.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest as to 1/12 of the total number of shares on July 7, 2023 and each monthly anniversary thereafter, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":3.28,"expiration_date":"2033-04-11","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-024288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919123024288/doc4.xml","form_type":"4"}},{"id":1919517,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-14T16:06:14.000Z","date":"2023-04-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested and continues to vest as to 1/36 of the total number of shares on February 1, 2023 and on each monthly anniversary thereafter, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":3.28,"expiration_date":"2033-04-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-024288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919123024288/doc4.xml","form_type":"4"}},{"id":1960825,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":1.6,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960824,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":4.62,"expiration_date":"2029-07-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960823,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2028-06-17","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960822,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":14.27,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960821,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":4386,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":10.79,"expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":4386},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960820,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":9.05,"expiration_date":"2026-07-27","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960819,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":9.28,"expiration_date":"2025-03-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960818,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.41,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960817,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T09:10:45.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":6.88,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":1960816,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T09:10:45.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":8386,"price":7.12,"value":59708.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-007654","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323007654/doc4.xml","form_type":"4"}},{"id":2028253,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T17:44:27.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":85000,"derivative":{"exercise_price":5.5,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0000899243-23-004204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323004204/doc4.xml","form_type":"4"}},{"id":2028252,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-07T17:44:27.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."}],"balance_after":42500,"derivative":{"underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0000899243-23-004204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924323004204/doc4.xml","form_type":"4"}},{"id":2129444,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-31T18:05:58.000Z","date":"2022-06-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 1, 2021, the reporting person was granted an award of restricted stock units, 100% of which vested and settled on June 15, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 1, 2021, the reporting person was granted an award of restricted stock units, 100% of which vested and settled on June 15, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-22-034577","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924322034577/doc4.xml","form_type":"4"}},{"id":2129443,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-10-31T18:05:58.000Z","date":"2022-10-27","kind":"grant","acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 42,500 shares."}],"balance_after":112992,"source":{"system":"sec-edgar","filing":"0000899243-22-034577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924322034577/doc4.xml","form_type":"4"}},{"id":2129442,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-10-31T18:05:58.000Z","date":"2022-06-15","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70492,"source":{"system":"sec-edgar","filing":"0000899243-22-034577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924322034577/doc4.xml","form_type":"4"}},{"id":2211663,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK","published_at":"2022-07-06T19:23:43.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":63492,"price":3.15,"value":199999.8,"ownership":{"direct":true},"balance_after":65492,"source":{"system":"sec-edgar","filing":"0000899243-22-025516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924322025516/doc4.xml","form_type":"4"}},{"id":2223985,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-22T17:06:49.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the Reporting Person's continued service as a director of the company."}],"balance_after":20000,"derivative":{"exercise_price":3.41,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919122038712/doc4.xml","form_type":"4"}},{"id":2408112,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-08T21:30:39.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":190000,"derivative":{"exercise_price":7.38,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0000899243-22-005316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924322005316/doc4.xml","form_type":"4"}},{"id":2679096,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-06-07T16:03:48.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 4, 2022, subject to the Reporting Person's continued service as a director of the company."}],"balance_after":20000,"derivative":{"exercise_price":6.88,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-038552","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919121038552/doc4.xml","form_type":"4"}},{"id":2680844,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:05:34.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":14800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021."}],"balance_after":14800,"derivative":{"exercise_price":15.26,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":14800},"source":{"system":"sec-edgar","filing":"0000899243-21-022014","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000089924321022014/doc4.xml","form_type":"4"}},{"id":2688767,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-06-01T21:25:15.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the restricted stock units will vest and settle on June 15, 2022.  The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the restricted stock units will vest and settle on June 15, 2022.  The restricted stock units have no expiration date."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-21-021446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924321021446/doc4.xml","form_type":"4"}},{"id":2688766,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-06-01T21:25:15.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 25% of the shares on June 1, 2022.  The remainder of the shares will vest and become exercisable in 12 equal quarterly installments thereafter."}],"balance_after":270000,"derivative":{"exercise_price":20.19,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0000899243-21-021446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924321021446/doc4.xml","form_type":"4"}},{"id":2716233,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-12T17:06:20.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":2229,"price":7.23,"value":16115.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $7.23.  The shares were sold at a range of prices between $7.14 and $7.23.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":220719,"source":{"system":"sec-edgar","filing":"0001209191-21-032103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121032103/doc4.xml","form_type":"4"}},{"id":2812630,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-03-03T18:26:11.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares shall vest on the one-year anniversary of January 1, 2021 (the \"Vesting Commencement Date\"), and thereafter 1/48th of the total shares shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four years after the Vesting Commencement Date."}],"balance_after":20000,"derivative":{"exercise_price":11.41,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-017248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017248/doc4.xml","form_type":"4"}},{"id":2812629,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T18:26:11.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":41900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":222948,"source":{"system":"sec-edgar","filing":"0001209191-21-017248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017248/doc4.xml","form_type":"4"}},{"id":2812628,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T18:26:11.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":181048,"source":{"system":"sec-edgar","filing":"0001209191-21-017248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121017248/doc4.xml","form_type":"4"}},{"id":2913589,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T17:50:04.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":6073,"price":11.13,"value":67592.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover tax withholding obligations associated with the vesting of restricted stock unit awards granted to the Reporting Person on March 1, 2019, and March 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.13.  The shares were sold at a range of prices between $11.12 and $11.47.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":151048,"source":{"system":"sec-edgar","filing":"0001209191-21-002558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919121002558/doc4.xml","form_type":"4"}},{"id":2931218,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-28T19:05:57.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":4347,"price":23,"value":99981.0,"ownership":{"direct":true},"balance_after":4347,"source":{"system":"sec-edgar","filing":"0000899243-20-035260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000089924320035260/doc4.xml","form_type":"4"}},{"id":2969701,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-11-23T11:16:19.000Z","date":"2020-11-19","kind":"other","acquired":false,"shares":1096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were called for redemption by the Issuer at their Black-Scholes value."}],"balance_after":0,"derivative":{"exercise_price":43.16,"exercise_date":"2017-05-24","expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":1096},"source":{"system":"sec-edgar","filing":"0000905718-20-001134","document":"springbank_fm4nov192020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000090571820001134/springbank_fm4nov192020.xml","form_type":"4"}},{"id":3079504,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-07-20T21:33:14.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":38750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023."}],"balance_after":157121,"source":{"system":"sec-edgar","filing":"0001209191-20-043120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120043120/doc4.xml","form_type":"4"}},{"id":3095141,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-01T17:22:08.000Z","date":"2020-06-29","kind":"grant","acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer."}],"balance_after":17400,"derivative":{"exercise_price":1.39,"expiration_date":"2030-06-29","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001209191-20-039815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919120039815/doc4.xml","form_type":"4"}},{"id":3099667,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T16:00:14.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":1.6,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-20-038874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919120038874/doc4.xml","form_type":"4"}},{"id":3100786,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-24T16:21:37.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":1303,"price":10.83,"value":14111.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,303 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":118371,"source":{"system":"sec-edgar","filing":"0001209191-20-038730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120038730/doc4.xml","form_type":"4"}},{"id":3154266,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-11T16:11:08.000Z","date":"2020-05-07","kind":"sale","acquired":false,"shares":2413,"price":10.88,"value":26253.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on June 1, 2018."}],"balance_after":117068,"source":{"system":"sec-edgar","filing":"0001209191-20-028249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120028249/doc4.xml","form_type":"4"}},{"id":3231884,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-03-03T16:14:39.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the \"Vesting Commencement Date\") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date."}],"balance_after":15500,"derivative":{"exercise_price":15.78,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-20-015120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120015120/doc4.xml","form_type":"4"}},{"id":3231883,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-03T16:14:39.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":119481,"source":{"system":"sec-edgar","filing":"0001209191-20-015120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120015120/doc4.xml","form_type":"4"}},{"id":3316222,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-07T16:31:01.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":3095,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 1, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at a range of prices between $19.76 and $19.91.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":88481,"source":{"system":"sec-edgar","filing":"0001209191-20-002279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919120002279/doc4.xml","form_type":"4"}},{"id":3326976,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-02T17:07:00.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":9098,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":37929,"source":{"system":"sec-edgar","filing":"0001209191-20-000377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919120000377/doc4.xml","form_type":"4"}},{"id":3402877,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-01T16:45:47.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":4179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":28831,"source":{"system":"sec-edgar","filing":"0001209191-19-051312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919119051312/doc4.xml","form_type":"4"}},{"id":3463491,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-07-11T08:52:45.000Z","date":"2019-07-10","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on July 10, 2019, the date of the Issuer's 2019 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":4.62,"expiration_date":"2029-07-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-041762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919119041762/doc4.xml","form_type":"4"}},{"id":3474612,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T08:58:24.000Z","date":"2019-06-28","kind":"grant","acquired":true,"shares":3896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to receive shares in lieu of cash compensation for services as a director and committee member."}],"balance_after":24652,"source":{"system":"sec-edgar","filing":"0001209191-19-039564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919119039564/doc4.xml","form_type":"4"}},{"id":3479984,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-24T16:10:17.000Z","date":"2019-06-21","kind":"grant","acquired":true,"shares":2152,"price":9.81,"value":21111.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 2,152 shares by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":91576,"source":{"system":"sec-edgar","filing":"0001209191-19-038758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119038758/doc4.xml","form_type":"4"}},{"id":3504531,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-03T16:18:03.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":2500,"price":11.0507,"value":27626.75,"ownership":{"direct":true},"balance_after":89424,"source":{"system":"sec-edgar","filing":"0001209191-19-033898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119033898/doc4.xml","form_type":"4"}},{"id":3525858,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-15T16:05:29.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":4000,"price":11.99,"value":47960.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $11.99, and the range of prices were between $11.9877 and $11.9879.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":86924,"source":{"system":"sec-edgar","filing":"0001209191-19-029970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119029970/doc4.xml","form_type":"4"}},{"id":3533549,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-09T16:32:58.000Z","date":"2019-05-08","kind":"sale","acquired":false,"shares":2248,"price":10.06,"value":22614.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on June 1, 2018."}],"balance_after":82924,"source":{"system":"sec-edgar","filing":"0001209191-19-028497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119028497/doc4.xml","form_type":"4"}},{"id":3568229,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T16:03:17.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":1370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer."}],"balance_after":20756,"source":{"system":"sec-edgar","filing":"0001209191-19-022328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919119022328/doc4.xml","form_type":"4"}},{"id":3604038,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-08T16:20:32.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":30600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities shall vest and become exercisable in equal quarterly installments starting on June 6, 2019 until the option is fully vested and exercisable on March 6, 2020, subject to continued service."}],"balance_after":30600,"derivative":{"exercise_price":4.07,"expiration_date":"2029-03-06","underlying":"Common Stock","underlying_shares":30600},"source":{"system":"sec-edgar","filing":"0001209191-19-018095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919119018095/doc4.xml","form_type":"4"}},{"id":3611874,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T16:27:56.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2019 (the \"Vesting Commencement Date\") and thereafter one-forty-eighth (1/48th) of the  total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date."}],"balance_after":18000,"derivative":{"exercise_price":14.75,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-19-016498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119016498/doc4.xml","form_type":"4"}},{"id":3611873,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-05T16:27:56.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":85172,"source":{"system":"sec-edgar","filing":"0001209191-19-016498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119016498/doc4.xml","form_type":"4"}},{"id":3703807,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-04T17:07:47.000Z","date":"2018-12-20","kind":"other","acquired":true,"shares":922,"price":10.48,"value":9662.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 922 shares by the Reporting Person on December 20, 2018 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":49172,"source":{"system":"sec-edgar","filing":"0001209191-19-002077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919119002077/doc4.xml","form_type":"4"}},{"id":3766772,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-13T09:14:51.000Z","date":"2018-11-09","kind":"purchase","acquired":true,"shares":4000,"price":16.5554,"value":66221.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $16.5554, and the range of prices were between $16.5461 and $16.5595.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":48250,"source":{"system":"sec-edgar","filing":"0001209191-18-058085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118058085/doc4.xml","form_type":"4"}},{"id":3847341,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-10T12:56:14.000Z","date":"2018-08-09","kind":"purchase","acquired":true,"shares":4000,"price":23.42,"value":93680.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $23.42, and the range of prices were between $23.3525 and $23.4288.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":44250,"source":{"system":"sec-edgar","filing":"0001209191-18-046163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118046163/doc4.xml","form_type":"4"}},{"id":3888392,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-19T16:37:18.000Z","date":"2018-06-18","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2018, the date of the Issuer's 2018 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":5500,"derivative":{"exercise_price":13.99,"expiration_date":"2028-06-17","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-18-038574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919118038574/doc4.xml","form_type":"4"}},{"id":3908199,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T16:26:08.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after May 7, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of May 7, 2018, so that all of the shares subject to the option shall be vested four (4) years after May 7, 2018."}],"balance_after":115000,"derivative":{"exercise_price":27.01,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-18-035083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118035083/doc4.xml","form_type":"4"}},{"id":3908198,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-04T16:26:08.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40250,"source":{"system":"sec-edgar","filing":"0001209191-18-035083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419600/000120919118035083/doc4.xml","form_type":"4"}},{"id":4241236,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-07T16:02:33.000Z","date":"2017-08-04","kind":"purchase","acquired":true,"shares":2300,"price":12.24,"value":28152.0,"ownership":{"direct":true},"balance_after":19386,"source":{"system":"sec-edgar","filing":"0001209191-17-047862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919117047862/doc4.xml","form_type":"4"}},{"id":4241235,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-07T16:02:33.000Z","date":"2017-08-04","kind":"purchase","acquired":true,"shares":200,"price":12.25,"value":2450.0,"ownership":{"direct":true},"balance_after":17086,"source":{"system":"sec-edgar","filing":"0001209191-17-047862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919117047862/doc4.xml","form_type":"4"}},{"id":4278890,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-16T16:46:58.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 15, 2017, the date of the Issuer's 2017 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":5500,"derivative":{"exercise_price":14.27,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-17-040557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000120919117040557/doc4.xml","form_type":"4"}},{"id":4542877,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2016-11-23T16:00:28.000Z","date":"2016-11-23","kind":"grant","acquired":true,"shares":4386,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4386,"derivative":{"exercise_price":10.79,"exercise_date":"2017-05-24","expiration_date":"2021-11-23","underlying":"Common Stock","underlying_shares":4386},"source":{"system":"sec-edgar","filing":"0000899243-16-034293","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924316034293/doc4.xml","form_type":"4"}},{"id":4542876,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":72639,"kind":"person","name":"Arkowitz David","position":1,"cik":"0001296999","reported_name":"Arkowitz David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-23T16:00:28.000Z","date":"2016-11-23","kind":"grant","acquired":true,"shares":4386,"price":9.12,"value":40000.32,"ownership":{"direct":true},"balance_after":16886,"source":{"system":"sec-edgar","filing":"0000899243-16-034293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296999/000089924316034293/doc4.xml","form_type":"4"}}]}